Company Profile

Biosense Technologies Inc
Profile last edited on: 3/29/19      CAGE: 3C1Q6      UEI:

Business Identifier: Rapid Microbiological Testing for Targeted Therapy
Year Founded
2002
First Award
2003
Latest Award
2016
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

4 Arrow Drive
Woburn, MA 01801
   (781) 933-3635
   info@biosensetech.com
   www.biosensetech.com
Location: Single
Congr. District: 05
County: Middlesex

Public Profile

Reported as having ceased operations in December 2018, BioSense Technologies had been a biomedical company developing technology used rapidly to diagnose infectious diseases. The company is working on platform technologies for testing clinical specimens that are able to identify antibiotic resistance and determine the most suitable treatment. Bacterial infection is a constant threat to the health of all people as antibiotic resistance, the ability of bacteria to defeat once powerful drugs, significantly challenges the ability to cure diseases and is an emerging crisis. The firm is developing Z-Sense technology, a new approach for treating infectious disease that is able to determine the susceptibility of bacteria to therapeutic agents in 30 minutes or less, significantly faster than currently used testing methods. The company is developing a proprietary new rapid platform technology to determine the chemosensitivity of difficult to culture cancer cells and antibiotic resistant infectious disease specimens. The technology is also being used to detect contaminant bacteria in complex samples and many other clinical applications.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2016 1 NIH $203,215
Project Title: Rapid Phenotypic Antibiotic Susceptibility Testing
2014 2 NIH $1,220,588
Project Title: Rapid Testing Of Drug-Resistant Bcr-Abl(+)Leukemia Cells
2010 2 NIH $876,054
Project Title: Rapid Diagnostic Testing of Urinary Tract Infections
2010 1 NIH $1,998,687
Project Title: Monitoring Physiological Stress: A Novel Biophysical Approach for the Rapid Detec
2008 2 NIH $910,503
Project Title: Rapid Detection of Bacterial Contamination in Platelets

Key People / Management

  Ronald J Rieder -- President

  Boris Zavizion -- Former Director of Biology

  Zhihui Zhao -- Senior Scientist

Company News

There are no news available.